Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) rose 4.3% during trading on Thursday . The company traded as high as $4.25 and last traded at $4.16, with a volume of 425,414 shares changing hands. The stock had previously closed at $3.99.

A number of analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Friday, July 29th. Cantor Fitzgerald lowered shares of Tobira Therapeutics to a “buy” rating and set a $19.00 price objective on the stock. in a research report on Monday, July 25th. Cowen and Company reiterated a “buy” rating and set a $11.00 price target on shares of Tobira Therapeutics in a report on Wednesday. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Finally, Leerink Swann reiterated a “buy” rating and set a $18.00 price target on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Five equities research analysts have rated the stock with a buy rating, Tobira Therapeutics presently has a consensus rating of “Buy” and an average target price of $14.95.

The stock’s 50-day moving average price is $8.72 and its 200-day moving average price is $8.38. The firm’s market capitalization is $86.74 million.

Tobira Therapeutics (NASDAQ:TBRA) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The business earned $1.06 million during the quarter. Equities analysts predict that Tobira Therapeutics Inc. will post ($2.65) EPS for the current fiscal year.

In other news, major shareholder A/S Novo sold 59,067 shares of the stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total transaction of $709,985.34. Following the sale, the insider now directly owns 1,914,541 shares of the company’s stock, valued at approximately $23,012,782.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP bought a new stake in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned about 0.57% of Tobira Therapeutics at the end of the most recent quarter.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.